J&J launches PhII lymphoma study for daratumumab

Genmab reports that its partners at J&J ($JNJ) are starting a Phase II study of daratumumab in non-Hodgkin's lymphoma. "With this study we are expanding the scope of the daratumumab development program, beyond multiple myeloma, into NHL, another disease area where new treatment options are needed, and where daratumumab has shown anti-tumor activity in pre-clinical disease models," said Jan van de Winkel, the CEO at Genmab. Release